By Mill Chart
Last update: Jan 9, 2024
JOHNSON & JOHNSON (NYSE:JNJ) has caught the attention of dividend investors as a stock worth considering. NYSE:JNJ excels in profitability, solvency, and liquidity, all while providing a decent dividend. Let's delve into the details.
ChartMill assigns a Dividend Rating to every stock. This score ranges from 0 to 10 and evaluates the different dividend aspects, including the yield, the growth and sustainability. NYSE:JNJ scores a 7 out of 10:
To gauge a stock's financial health, ChartMill utilizes a Health Rating on a scale of 0 to 10. This comprehensive evaluation encompasses liquidity and solvency, both in absolute terms and in comparison to industry peers. NYSE:JNJ has earned a 7 out of 10:
ChartMill employs its own Profitability Rating system for stock evaluation. This score, ranging from 0 to 10, is derived from an analysis of diverse profitability metrics and margins. In the case of NYSE:JNJ, the assigned 9 is noteworthy for profitability:
More Best Dividend stocks can be found in our Best Dividend screener.
For an up to date full fundamental analysis you can check the fundamental report of JNJ
This article should in no way be interpreted as advice in any way. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.
JOHNSON & JOHNSON
NYSE:JNJ (4/19/2024, 7:04:00 PM)
After market: 147.89 -0.02 (-0.01%)147.91
+2.17 (+1.49%)
As uncertainty in the global economy and geopolitical climate abounds, investors should focus on stocks with proven track records.
Small-cap stocks have been the market laggards but these standouts showed how to beat even top-tier tech names at their own game.
The Nasdaq and S&P 500 tumbled below their 50-day lines.
This is what could happen next to Johnson & Johnson shares.
NVIDIA, Alphabet, Johnson & Johnson, Broadridge Financial and Textron are included in this Analyst Blog.
A Florida jury on Thursday concluded that Johnson & Johnson's baby powder talc product did not cause the ovarian cancer of a Florida woman who died in 2019. The lawsuit was brought by family members of Patricia Matthey, a Sarasota County resident who used Johnson's baby powder daily from 1965 until August 2016, when she was diagnosed with ovarian cancer, according to her family's lawsuit. J&J's Worldwide Vice President of Litigation Erik Haas said the company was vindicated by the jury's decision.
Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), Alphabet Inc. (GOOGL) and Johnson & Johnson (JNJ).
Discover recession-proof stocks that thrive amid economic uncertainty, offering stability and consistent growth.
Investors wondering which tax refund stocks to invest in should consider these names, each of which is a capital compounder.
Top S&P500 movers in Thursday's after hours session
Balancing Dividends and Fundamentals: The Case of JOHNSON & JOHNSON (NYSE:JNJ).